![institutions-DFCI-Logo-500px-rgb[2]20221027132117.jpg](/images/institutions/logos/DFCI-Logo-500px-rgb[2]20221027132117.jpg){kind=logo}
With the start of a new year, Dana-Farber Cancer Institute experts are encouraging people to ring in new healthy habits and offer a number of free and low-cost strategies to help people maintain good health and possibly reduce various cancer risks.
Dana-Farber has launched Insight, a blog offering expert commentary on cancer research and care advances and insight on issues and topics relevant to cancer patients. Insight also will feature perspectives on treatment options and provide information that is not available in traditional media outlets.
In an African county lacking any specialists in children’s cancers, a team approach that “twins” Rwandan physicians with Boston-based pediatric oncologists has shown it can deliver expert, curative care to young patients stricken with lymphoma.
Scientists at Dana-Farber Cancer Institute have created a “cocktail” of immune-stimulating peptides they believe could provoke the body’s defenses to attack multiple myeloma in its early “smoldering” phase and slow or prevent the blood cancer.
Dana-Farber Cancer Institute researchers say when the targeted drug bortezomib stops working in patients with advanced multiple myeloma, the patients survive only an average of five months longer. But a phase 2 clinical trial has shown that pairing bortezomib with an experimental drug, panobinostat, may be a promising new treatment for such patients.
Scientists at Dana-Farber Cancer Institute have identified a gene mutation that underlies the vast majority of cases of Waldenstrom’s macroglobulinemia, a rare form of lymphoma that has eluded all previous efforts to find a genetic cause.
A therapy involving a natural compound may improve the ability of stem cells from umbilical cord blood to engraft in patients receiving a stem cell transplant for cancer or other diseases, a phase I clinical trial led by Dana-Farber Cancer Institute scientists indicates.
Experts from Dana-Farber Cancer Institute offer some tips to pick festive foods that may even fight cancer.
The most comprehensive search to date of DNA abnormalities in chronic lymphocytic leukemia (CLL) has unearthed several new altered genes that drive this common blood cancer, a finding that could potentially help doctors predict whether an individual patient’s disease will progress rapidly or remain indolent for years.
Researchers at Dana-Farber Cancer Institute have identified a mechanism in mice that triggers inflammation in the liver and transforms normal cells into cancerous ones.
Hormone-blocking therapy for prostate cancer doesn’t raise the risk of fatal heart attacks – as some recent studies had suggested – according to a new report from Dana-Farber/Brigham and Women’s Cancer Center.
Scientists at Dana-Farber Cancer Institute have used IL-2, an immune system stimulant, as an immune system suppressor to treat a common, often debilitating side effect of donor stem cell transplantation in cancer patients. The effect, in some cases, was profound.
Two-drug combination may alleviate radiation sickness in people.
Dana-Farber scientists have devised a test that can predict how effective chemotherapy will be by determining whether tumor cells are "primed" for death. The discovery suggests it may be possible to predict which patients will likely benefit from chemo, as well as to make some chemo more effective.
Dana-Farber and Brigham and Women’s Hospital have launched a research program to scan adult cancer patients’ tumor tissue for nearly 500 cancer mutations in 41 genes. The goal is to build a comprehensive database for research into the genetic makeup of different cancer types and, ultimately, the development of more treatments.
Scientists at Dana-Farber Cancer Institute and the Broad Institute have found strikingly high levels of a bacterium in colorectal cancers, a sign that it might contribute to the disease and potentially be a key to diagnosing, preventing, and treating it.
Scientists at Dana-Farber Cancer Institute and Harvard Medical School have found that a common cancer protein leads a second, totally different life in normal adult brain cells: It helps regulates memory formation and may be implicated in Alzheimer's disease.
The American Association for Cancer Research (AACR), releases its AACR Cancer Progress Report 2011, in which its calls on Congress to increase funding for the National Institutes of Health (NIH) and the National Cancer Institute (NCI).
Researchers from Dana-Farber and the Scripps Research Institute in Jupiter, Fla., have created prototype drugs that have powerful anti-diabetic effects and are free of dangerous side effects plaguing some current diabetes medications.
Dana-Farber researchers successfully disrupted the function of the gene MYC by tampering with the gene's "on" switch and growth signals in multiple myeloma cells, offering promising strategy for treating myeloma and other cancers driven by the MYC gene.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right